Reform Marijuana Laws NORML Site Map Contact Us About Marijuana Law Reform Media Contact About Marijuana Law Reform Home
Working to reform marijuana laws
search by
Click here to navigate by map
State Laws | Leyes Estatales
 
 
 
 
 
Get NORML's eZine
Meet Others, Share Stories
Get NORML's eZine
Legislative Alerts, News & Analysis from NORML

Details & Privacy


Home > News Archive > 2001 > Marijuana Spray Reduces MS Patients' Pain, Spasms, Study Finds

Marijuana Spray Reduces MS Patients' Pain, Spasms, Study Finds

Share This Page Share This Page on digg Share This Page on Reddit Share This Page on del.icio.us Share This Page on Stumble Upon Share This Page on Facebook Share This Page on Twitter

May 2, 2001 - London, England

Marijuana extracts administered under the tongue greatly reduce pain, muscle spasms and bladder dysfunction in patients with multiple sclerosis, according to results of a Phase II study recently completed by GW Pharmaceuticals in England.
Seventy subjects participated in the study. Patients consumed marijuana as a sublingual spray, which allows it to be absorbed rather than swallowed. Patients began experiencing relief two to three minutes after administration, GW Pharmaceuticals spokesman Mark Rogerson said.
"It makes the pain go away," Rogerson told Bloomberg news. "It also helps multiple sclerosis patients control their limbs and get a good night's sleep" because they can control their bladders. Patients' neurological function was also improved by medical marijuana, he said.
The company announced that it expects to begin Phase III trials shortly, and will also be commencing preliminary trials in Canada.
A 1999 study by the U.S. Institute of Medicine reported: "Basic animal studies ... have shown that cannabinoid receptors are particularly abundant in areas of the brain that control movement and that cannabinoids affect movement and posture in animals as well as humans. The observations are consistent with the possibility that cannabinoids have antispastic effects ... and carefully designed clinical trials testing the effects of cannabinoids on muscle spasticity should be considered."
GW Pharmaceuticals has been growing medical marijuana for research purposes in cooperation with British Home Office authorities since 1997, and hopes to bring a medical-marijuana spray to market by 2003.
For more information, please contact Paul Armentano of The NORML Foundation at (202) 483-8751.

    updated: Jan 05, 2002

Share This Page Share This Page on digg Share This Page on Reddit Share This Page on del.icio.us Share This Page on Stumble Upon Share This Page on Facebook Share This Page on Twitter

2009   2008   2007   2006   2005   2004   2003   2002   2001   2000   1999   1998   1997   1996  
Country State/Prov Year Month
Join the NORML Legal Committee
Features
Features
   
NORML
Site MapContact UsSupport NORMLTake ActionLibrary
© 2009 NORML • Privacy StatementSite Terms • Site by Communicopia and Red Aphid
NORML and the NORML Foundation: 1600 K Street NW, Suite 501, Washington DC, 20006-2832
Tel: (202) 483-5500 • Fax: (202) 483-0057 • Email: norml@norml.org